Home Featured Page 160

Featured

Latest

No Questions Asked: FDA’s Psychedelics Public Hearing

Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder

THE GATEWAY: Live From DC After the FDA Psychedelics Hearing

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

PsyBio Therapeutics Reaches Agreement to Conduct Initial Psilocybin Clinical Trial

PT363 – Reggie Harris – Cannabis and Psilocybin: The Complications of...

Optimi Health Announces Closing of Strategic Non-Brokered Private Placement

Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for...

The Fifteenth Horizons is Right Around the Corner

Numinus to Participate in a Water Tower Research Fireside Chat on...

Reunion Neuroscience Inc. Announces Executive Changes

PT362 – Cory Firth – Psychedelic Storytelling: Transforming Out Loud

Alberta Puts Patients First By Regulating Psychedelic Therapy: Optimi Health

Silo Pharma to Present at the Dawson James Small Cap Growth...

EDITOR PICKS

No Questions Asked: FDA’s Psychedelics Public Hearing

Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder

THE GATEWAY: Live From DC After the FDA Psychedelics Hearing

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

No Questions Asked: FDA’s Psychedelics Public Hearing

Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder

THE GATEWAY: Live From DC After the FDA Psychedelics Hearing

Approvals to Access: A Crude Schematic

Davis, Farchione and Colleagues Present FDA’s Psychedelic Drug Framework in NEJM

PsyBio Therapeutics Reaches Agreement to Conduct Initial Psilocybin Clinical Trial

PT363 – Reggie Harris – Cannabis and Psilocybin: The Complications of...

Optimi Health Announces Closing of Strategic Non-Brokered Private Placement

Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for...

The Fifteenth Horizons is Right Around the Corner

Numinus to Participate in a Water Tower Research Fireside Chat on...

Reunion Neuroscience Inc. Announces Executive Changes

PT362 – Cory Firth – Psychedelic Storytelling: Transforming Out Loud

Alberta Puts Patients First By Regulating Psychedelic Therapy: Optimi Health

Silo Pharma to Present at the Dawson James Small Cap Growth...

EDITOR PICKS

No Questions Asked: FDA’s Psychedelics Public Hearing

Definium Notches Second Positive Phase 3 in Generalised Anxiety Disorder

THE GATEWAY: Live From DC After the FDA Psychedelics Hearing

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY